In addition, paclitaxel can transform B-cell lymphoma 2 (Bcl-2) anti-apoptotic to pro-apoptotic activity by binding to the N-terminal loop of Bcl-2; thus, paclitaxel-resistant cancer cells can counteract this pro-apoptotic activity by increasing the expression of Bcl-2 family anti-apoptotic members [25,26]. Here, BCL2 is linked to cancer.